Andrew Aromando

Andrew Aromando is an accomplished biopharmaceutical executive with over 30 years of industry experience. He has a proven track record of demonstrated expertise in oncology portfolio optimization, corporate development and operational excellence. Prior to Oncolytics, he served in C-level positions for 20 years at multiple oncology-focused biotech and specialty pharmaceutical companies, where he crafted and led corporate strategy, acquired and advanced clinical-stage candidates, developed and executed commercialization plans for marketed products that increased sales, and negotiated successful exits. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. He also served in senior leadership roles at IQVIA, Syneos Health and WCG Clinical, leading teams focused on the development of clinical and commercial solutions for early, mid- and late-stage drug candidates, new products and mature brands across therapeutic areas. He began his career in field sales at Novartis. Mr. Aromando holds a B.A. from The College of New Jersey and an M.A. from Rutgers University.